Loading
institutionsInstitution
Princess Margaret Cancer Centre
Princess Margaret is Canada's leading cancer centre and a pioneer in immunotherapy and cancer stem cell research.
Overview
Princess Margaret Cancer Centre in Toronto is Canada's leading cancer centre and ranks ninth in the Newsweek/Statista oncology list. It is where John E. Dick's group identified cancer stem cells, and it runs a major phase 1 unit under Lillian L. Siu alongside tumour-infiltrating lymphocyte and radiation medicine research, with Tak W. Mak, Pamela S. Ohashi and Aaron D. Schimmer among its scientists. OnCo links it to the CHALLENGE colon cancer exercise trial, to cBioPortal, to the cancer stem cell and phenotypic plasticity pathway, and to Ontario Health, the Ontario Institute for Cancer Research and the Canadian Cancer Society. Whether stem cell biology can yet be turned into treatments patients feel is still open. Its people page shows who to read.
Location
Toronto, CA
Type
cancer center · University of Toronto
Website
Newsweek 2026 oncology rank
#9
OnCo score
#22 · 89 points (51 Newsweek + 0 NCI + 38 from 19 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-24.
Matched to Princess Margaret Cancer Centre, including child institutions. 1,477 works · 21,748 citations · 66% open access · 15% clinical trials · 3% reviews.
Oncology works per year
3242022
3302023
2852024
3362025
2022026
Most works
- Marcus Otho Butler73 works
- Lillian L. Siu66 works
- John G. Kuruvilla63 works
- Anna Spreafico58 works
- Philippe Lucien Bedard54 works
- Geoffrey Liu52 works
- Monika Karolina Krzyzanowska51 works
- Amit M. Oza48 works
- Benjamin Hoyin Lok45 works
- David W. Cescon43 works
Most cited
- Cancer stem cells
- Phase 1
- Radiation medicine
A. Keith Stewart
Director, Princess Margaret Cancer Centre; Vice President, Cancer, University Health Network
Multiple myelomaCancer genomicsAcademic leadership
Keith Stewart is a myeloma researcher who leads Canada's largest cancer centre.
Aaron D. Schimmer
Research Director, Princess Margaret Cancer Centre; Senior Scientist
AMLMitochondrial metabolismDrug repurposing
Leukaemia researcher who found that AML stem cells depend on mitochondrial proteases and metabolism.
Amit M. Oza
Head, Division of Medical Oncology and Hematology; Director, Cancer Clinical Research Unit
Ovarian cancerPARP inhibitorsGynaecologic trials
Amit Oza is a gynaecologic oncologist who led early olaparib and niraparib studies in ovarian cancer.
Ian F. Tannock
Emeritus Professor of Medical Oncology, Princess Margaret Cancer Centre and University of Toronto
Trial methodologyProstate cancerClinical benefit assessment
Led TAX 327, which made docetaxel the first life-extending chemotherapy for prostate cancer, and has spent decades pressing for higher trial standards.
John E. Dick
Senior Scientist, Princess Margaret Cancer Centre; Canada Research Chair in Stem Cell Biology
Leukaemia stem cellsHaematopoiesisPre-leukaemic clones
Discovered cancer stem cells, showing leukaemia is driven by a rare population of self-renewing cells.
Lillian L. Siu
Director, Phase I Program; BMO Chair in Precision Cancer Genomics
Early drug developmentHead and neck cancerImmunotherapy
Runs one of the world's largest phase 1 programmes and led trials that shaped head and neck cancer immunotherapy.
Natasha B. Leighl
Lung Site Lead, Medical Oncology; OSI Pharmaceuticals Foundation Chair in Cancer New Drug Development
Lung cancerLiquid biopsyHealth economics
Lung cancer oncologist who showed plasma genotyping matches tissue and leads Canadian lung trials.
Pamela S. Ohashi
Director, Tumour Immunotherapy Program; Co-Director, Campbell Family Institute for Breast Cancer Research
T-cell toleranceTIL therapyTumour immunology
Immunologist who built Canada's TIL therapy programme and defined T-cell tolerance mechanisms.
Tak W. Mak
Senior Scientist, Princess Margaret Cancer Centre; University Professor, University of Toronto
T-cell receptorImmunologyCancer metabolism
Cloned the T-cell receptor and co-discovered CTLA-4's brake function, foundations of modern immunotherapy.
Trevor J. Pugh
Senior Scientist, Princess Margaret; Director of Genomics, Ontario Institute for Cancer Research
Cancer genomicsctDNASingle-cell sequencing
Genomicist who applies cell-free DNA and single-cell sequencing to track cancer and immunotherapy response.
translationalCell 2021366 citations
Spatially confined sub-tumor microenvironments in pancreatic cancer
It explains why one biopsy can mislead and why chemotherapy selects for the protective neighbourhood, an argument for spatial rather than bulk profiling.
translationalClinical Cancer Research 2020307 citations
GATA6 expression distinguishes classical and basal-like subtypes in advanced pancreatic cancer
It is the number behind 'basal-like is chemoresistant' and the validation of the GATA6 stain that lets a pathology laboratory call the subtype without RNA sequencing.
translationalNature Genetics 2020591 citations
Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution
It explains why single-sample classifiers disagree on about one tumour in eight and why KRAS allelic imbalance and GATA6 copy number are being read alongside expression.
translationalClinical Cancer Research 2018531 citations
Genomics-driven precision medicine for advanced pancreatic cancer: early results from the COMPASS trial
COMPASS is the prospective evidence that transcriptional subtype predicts chemotherapy response, and it produced the practical GATA6 test that trials now use to stratify.
translationalJAMA Oncology 2017217 citations
Association of distinct mutational signatures with correlates of increased immune activity in pancreatic ductal adenocarcinoma
Signatures find repair-deficient tumours that gene panels miss, and they mark the minority in which checkpoint drugs have a rationale.
translationalNature 2016429 citations
A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns
The textbook PanIN-to-cancer ladder is only part of the story, and a screening programme cannot assume years of orderly progression in every patient.
observationalBritish Journal of Cancer 2014347 citations
Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers
The retrospective platinum signal that made platinum-based first-line chemotherapy the standard for BRCA carriers and set POLO's design of olaparib after platinum.
Similar pages
- TermCOMPASS: real-time sequencing of advanced pancreatic cancer for treatment selection
Shares Genomics-driven precision medicine for advanced pancreatic cancer: early results from the COMPASS trial, GATA6 expression distinguishes classical and basal-like subtypes in advanced pancreatic cancer, Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution.
- TermGATA6 as the marker of classical versus basal-like pancreatic cancer
Shares Genomics-driven precision medicine for advanced pancreatic cancer: early results from the COMPASS trial, GATA6 expression distinguishes classical and basal-like subtypes in advanced pancreatic cancer, Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution.
- CompanyCanadian Cancer Trials Group (CCTG)
Shares Canadian Cancer Society, Health Canada, Sunnybrook Odette Cancer Centre, CHALLENGE (CCTG CO.21).
- TermKRAS allelic imbalance and mutant KRAS dosage in pancreatic cancer
Shares A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns, Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution.
- Key paperSingh 2004: identification of human brain tumour initiating cells
Shares The Hospital for Sick Children (SickKids), Cancer stem cells & phenotypic plasticity.
- TermWhole-genome doubling (WGD)
Shares A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns, Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution.
institutions
pathways
trials
ideas
collections
people
key papers
A renewed model of pancreatic cancer evolution based on genomic rearrangement patternsAssociation of distinct mutational signatures with correlates of increased immune activity in pancreatic ductal adenocarcinomaGATA6 expression distinguishes classical and basal-like subtypes in advanced pancreatic cancerGenomics-driven precision medicine for advanced pancreatic cancer: early results from the COMPASS trialOverall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriersSpatially confined sub-tumor microenvironments in pancreatic cancerTranscription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution
Open-source projects
All open source in oncology →Open-source projects that this organisation maintains, from OnCo's own catalogue: licence and last activity as the repository reported them on the day of the fetch. Listing is not endorsement; check the licence before reuse and the validation before clinical use.
A Bioconductor package for analysing large pharmacogenomic datasets such as GDSC and CCLE, from the Haibe-Kains lab.
Turns messy DICOM folders into analysis-ready arrays with RTSTRUCT and dose handling, from the Haibe-Kains lab.
A Bioconductor package implementing the published breast cancer molecular subtype and prognostic gene signatures, including PAM50.
A Python client for The Cancer Imaging Archive's NBIA API from the Haibe-Kains lab.